Kornimate/medical-research-clean huggingface dataset:
prospective, multi-center clinical evaluation of the open wedge osteotomy and low profile plate & screw (lps) system compared to the proximal chevron osteotomy for the treatment of hallux valgus with an increased intermetatarsal angle

Conditions: Hallux Valgus

Summary: is there a difference in clinical outcome measures as assessed by the aofas, sf-36 and visual analogue scale of adult patients with moderate to severe hallux valgus with increased intermetatarsal angles treated with a proximal open wedge osteotomy with lps system versus the proximal chevron osteotomy?

is there a difference in radiologic outcomes of adult patients with moderate to severe hallux valgus with increased intermetatarsal angles treated with a proximal open wedge osteotomy with lps system versus proximal wedge osteotomy? is there a difference in surgical times or surgeon procedure preference in the treatment of adult patients with moderate to severe hallux valgus with increased intermetatarsal angles treated with a proximal open wedge osteotomy with lps system versus proximal wedge osteotomy? is there a difference in complication rates of adult patients with moderate to severe hallux valgus with increased intermetatarsal angles treated with a proximal open wedge osteotomy with lps system versus proximal wedge osteotomy?

Eligibility criteria:
inclusion criteria: * age (\> 16 years of age) moderate to severe hallux valgus angle \[hva\] of \>30º with increased intermetatarsal angles \[ima\] of \>13º * persistent incapacitating symptoms despite non-operative treatment (shoe wear modification, orthoses, non-steroidal anti-inflammatory drugs and restricted activity) exclusion criteria: * degenerative arthritis of 1st metatarsophalangeal (mtp) joint * neuropathic patients * diabetes mellitus * peripheral vascular disease * previous 1st metatarsal, hallux or mtp joint surgery * active or recent foot/toe infection * currently participation in a another clinical trial * worker's compensation board patients.
feasibility study: evaluation of the ulthera® system for treatment of the knees

Conditions: Skin Laxity

Summary: enrolled subjects will receive one bilateral ulthera® treatment on the knees. up to 30 subjects will be enrolled. study photos will be obtained prior to study treatment, immediately following study treatment, and at each post-treatment follow-up visit. follow-up visits will occur at 90 and 180 days post-treatment.

this pilot study is a prospective, single-center clinical trial of the ulthera® system for treating skin laxity on the knees. global aesthetic improvement scale scores and patient satisfaction questionnaires will be obtained at each follow-up visit.

Eligibility criteria:
inclusion criteria: * female, aged 30 to 65 years. * subject in good health. * mild to moderate skin laxity around the knees. * understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period. exclusion criteria: * presence of an active systemic or local skin disease that may affect wound healing. * excessive subcutaneous fat around the knees. * excessive skin laxity around the knees.

Keywords: skin laxity knees
comparison of adverse drug reactions associated for oxycodone and morphine in postoperative pain after abdominal hysterectomy

Conditions: Pain, Postoperative

Summary: the objective of this study is compare adverse reactions associated with oxycodone and morphine for the treatment of postoperative pain after abdominal hysterectomy

a randomized single-blind study, was performed to compare the adverse reactions associated with oxycodone and morphine in patients undergoing abdominal hysterectomy. process: 1. a clinical history of patients candidates to participate in the study will be developed. 2. if you meet the selection criteria will be held the invitation to participate in the study, reading the letter under information patients who agree to participate in the study will be managet during the surgical procedure: 15 mg mixed blockade with bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg intravenously during surgery metamizol 3) after the surgical procedure (immediate postoperative) • the patient to group a or b (randomization) is assigned, masking infusions and allocation will be conducted by an outside person who will test an additional record the names of the patients and the drug administered. a bolus of oxycodone or morphine 10% calculated dose for intravenous infusion 0.075mg intravenous palonosetron prophylaxis of emesis detection and assessment of severity of adverse drug reactions will be conducted by an interview that will be at 0,1,2,6,12 and 24 hours after the onset of analgesia. instrument designed for the detection of ram will be used and classify its severity according to common terminology criteria for adverse events (ctcae). futhermore, measuring systemic blood pressure, heart rate, oxygen saturation will be performed through the use of nihon kohden monitor (model bsn-2301k). pain assessment will be made by the numerical scale (nrs). the researcher responsible for the detection and assessment of adverse reactions to opioids and others determinations, remain mowed.

Eligibility criteria:
inclusion criteria: * patients scheduled for abdominal hysterectomy * signing for informed consent exclusion criteria: * patients used with mao inhibitor drugs (\<14 days before surgery) * history of substance abuse * hypersensitivity to opioids and others drugs of multimodal analgesia (metamizol and lidocaine) * pretreatment of any opioid (\<7/2 lives of the drug in question) * chronic pain of any etiology (\> 6 months) * diagnosis of bowel obstruction * renal or hepatic insufficiency * asthma, chronic obstructive pulmonary disease (copd), and/ or hypothyroidism. * patients requiring general anesthesia for surgical complications

Keywords: adverse drug reaction morphine oxycodone abdominal hysterectomy
observe abnormal potential from the offending vessel to the facial muscles of hfs patients

Conditions: Hemifacial Spasm

Summary: the pathophysiologic basis of hemifacial spasm is cross-transmission between different branches of the facial nerve. the hypothesis is that the cross-transmission is mediated by the sympathetic nerve fibers on the surface of the offending artery. the abnormal potential from the offending vessel to the facial muscles will be detected on hemifacial spasm patients, so as to determine if the sympathetic nerve fibers take part in the circuit of cross-transmission.

it's hypothesized that at the location where the facial nerve is compressed by an artery, ephaptic cross-transmission takes place between the nude facial nerve fibers and the sympathetic nerve fibers on the arterial surface. thus action potentials could spread indirectly from one facial nerve fiber to several other facial nerve fibers (via the "bridge" of sympathetic fibers), or directly from the sympathetic fibers to facial nerve fibers. the investigators assume this is the electrophysiological basis of hemifacial spasm and its characteristic sign abnormal muscle response (amr). if an abnormal potential from the offending artery to the facial muscles similar to amr can be recorded, the hypothesis will be verified.

Eligibility criteria:
inclusion criteria: 1. the age of 18-65 years old; 2. with typical hemifacial spasm symptoms; 3. with typical abnormal muscle response; 4. preoperative magnetic resonance imaging revealed obvious paraneural artery; 5. with informed consent. exclusion criteria: 1. pregnant or lactating women; 2. accompanied by other serious diseases, including liver, kidney, cardiovascular diseases; 3. accompanied by mental illness or severe neurosis; 4. unable to express the subjective symptoms.

Keywords: cross-transmission offending vessel
treatment of chronic migraine with erenumab alone or as an add on therapy

Conditions: Refractory Chronic Migraine

Summary: treatment of chronic migraineurs who have failed more than 3 preventive drugs with erenumab alone, to reduce frequency of monthly migraine days or as an add on therapy

the investigators treated chronic migraineurs that have failed more than 3 preventive drugs with erenumab alone or as an add on therapy to: reduce the frequency of monthly migraine days, to evaluate if the add on of erenumab to another preventive therapy is superior to erenumab alone, and assess all adverse events related to the use of erenumab. migraineurs with 15-30 migraie days per month at baseline were clustered in 3 categories. failure of erenumab was defined as no improvement in the frequency of monthly migraine days. group i: no preventive therapy, prior to the start of erenumab. (no botox cohort). group ii: on botulinum toxin a (botox), prior to the add on therapy with erenumab. (botox cohort).group iii: on an oral preventive drug, prior to the add on therapy with erenumab. (no botox cohort)

Eligibility criteria:
inclusion criteria: * chronic migraineurs with failure to more than 3 preventive treatments * naive to anti cgrp monclonal antibodies exclusion criteria: * episodic migraineurs, * other headache types
de quervain syndrome among medical students with smart phone addiction

Conditions: De Quervain Tenosynovitis; Smartphone Addiction

Summary: to investigate the prevelance of the de quervain tenosynovitis among the egyptian medical students with smartphone addiction

addictive participants will be assigned and enrolled in the study according to there addiction score on smartphone addiction scale. participants will receive a finkelstein test for both dominant and non dominant hand for the de quervain tenosynovitis. then the strentgh of both hand grip and pinch grip for both hands will be tested using hand grip strength dynamometer and pinch strentgh dynamometer.

Eligibility criteria:
inclusion criteria: * asymptomatic students with normal healthy state * any student in all the academic years with age 18-25 * addictive smart phone users with score over 31 for male and 33 for female students in smart phone addiction scale. * who own or use mobile. * both genders: male and female * willing to participate. * egyptian students exclusion criteria: * those who don't have mobile phone. * any previous injury or trauma or surgery and a history of rheumatoid arthritis, osteoarthritis, and deformities and changes in the shape of the finger joints. * those who are not willing to participate. * non-egyptian students.

Keywords: de quervain tenosynovitis egyptian medical students cairo university smartphone addiction prevelance
evaluation of the effects of a-prf and oral dexamethasone use in third molar extraction

Conditions: Wisdom Tooth Removal

Summary: impacted third molar tooth extraction is one of the most frequently performed procedures in oral surgery. complications such as pain, swelling and trismus, which are frequently seen after this operation, affect the patient's quality of life in the postoperative period. today, there are many methods used to prevent or treat these complications. corticosteroid use and a-prf biomaterial obtained from the patient's own blood are some of these methods. in patients with bilaterally impacted lower wisdom teeth, a-prf was applied to one side after extraction and postoperative oral dexamethasone was used to the other side. intra-group and inter-group evaluations were made by collecting the patients' pain, edema, trismus and analgesic use data.

impacted third molar tooth extraction is one of the most commonly performed procedures in oral surgery. complications such as pain, swelling and trismus, which are frequently seen after this operation, affect the quality of life of the patient in the postoperative period and may cause patients to avoid this procedure. today, there are many methods used to prevent or treat these complications. the use of corticosteroids and the a-prf biomaterial obtained from the patient's own blood are some of these methods. no study has been found in the literature comparing the effects of oral use of dexamethasone, a corticosteroid drug, with a-prf on pain, edema, trismus and analgesic use. in patients with bilateral impacted lower wisdom teeth, a-prf was applied to the extraction site after extraction on one side and postoperative oral dexamethasone was used on the other side. pain, edema, trismus and analgesic use data of the patients were collected and in-group and intergroup evaluations were made.

Eligibility criteria:
inclusion criteria: * not having any systemic disease, * being over 18 years of age, * bilateral teeth being in similar positions and being completely impacted, * not having any allergies to the drugs to be used in the study. exclusion criteria: * infection in the area where the extraction will be performed, * pregnancy or breastfeeding, * using medication up to 2 weeks before tooth extraction, * not using prescribed medications regularly, * not coming to regular check-ups.

Keywords: third molar a-prf dexamethasone postoperative complication
histology of functional density in premenopausal breast

Conditions: Dense Breasts; Breast Cancer

Summary: the investigators hypothesize that knowledge of the functional behavior of areas of mammographic density will enable more specific identification of dense tissue at-risk for breast cancer, ultimately providing predictive information on an individual's risk of developing breast cancer.

the specific aims are: * in women with increased mammographic density (md), determine the histological characteristics of functionally dense tissue compared to that of non-functionally dense tissue via core-needle biopsy of the breast. * in women with increased mammographic density (md), determine the correlations between the total percent area of functional density (fd) on mbi, percent density of md on mammogram, and histological characteristics of dense tissue

Eligibility criteria:
inclusion criteria: * ages 40 - 55 years * considered premenopausal or peri-menopausal * screening mammogram performed at mayo clinic rochester within one year prior to the current mbi study which demonstrates * negative/benign assessment (birads category 1-2) or additional imaging recommended (birads category 0), where the subsequent diagnostic workup results in a final negative/benign assessment (birads category 1-2). * no proliferative benign lesions (e.g. fibroadenomas) identified * heterogeneously dense or extremely dense parenchyma (birads density category 3 or 4) * mbi performed less than 3 days prior to biopsy demonstrating either marked fd or photopenic fd in an area of mammographically dense tissue amenable to biopsy. * no use of exogenous hormonal drugs (e.g. hormonal contraceptives or sex steroid hormones) within six months prior to study biopsy * negative pregnancy test or surgically sterilized (for patients in whom a study mbi will be performed) exclusion criteria: * using any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or any aromatase inhibitors within six months prior to study biopsy. * prior diagnosis of bilateral breast cancer. * diagnosis of breast cancer in either breast within 3 years prior to study mbi. * diagnosis of any cancer, except breast cancer (see #3) or non-melanomatous skin cancer, for which patient has not been disease free for at least 5 years. * current breast symptoms * breast implants * known allergy to local anesthetic. * history of bleeding complications from prior interventions * current use of anticoagulants (e.g., coumadin or other blood thinners) * major medical condition
gambit task with ptsd and healthy control participants

Conditions: Posttraumatic Stress Disorder

Summary: this is a pilot study of a digital training task called gambit. this study will be the first to examine potential relationships between gambit task completion and brain circuit flexibility, behavior, and symptoms in participants with ptsd.

this is a single-site pilot study for the gambit intervention, which is a computerized task that addresses behavioral inhibition. the primary objective of this study is to determine whether the gambit task improves mental health symptoms associated with ptsd over time. the secondary objective of this study is to determine whether the gambit task promotes flexibility in inhibitory control network as determined by functional neuroimaging. additional laboratory measures associated with cognitive flexibility, and clinician and patient-rated symptom data, will be collected.

Eligibility criteria:
inclusion criteria: * male or female aged 18-55 years * participants must be able to provide informed consent * participants must have a level of understanding of the english language sufficient to agree to all tests and examinations required by the study and must be able to participate fully in the informed consent process * must meet criteria for one of the following study groups: * ptsd group: i. meets diagnostic criteria for current ptsd according to the diagnostic and statistical manual of mental disorders-fifth edition (dsm-5) 1. has been exposed to a criterion a trauma of the civilian type (e.g., non-combat, threatened or actual interpersonal violence) or non-civilian 2. must have a total score ≥ 25 on the caps-5 (past-month version) at the time of screening, indicating moderate ptsd symptom severity. * healthy control group: i. has no lifetime history of any psychiatric disorder exclusion criteria: * current or lifetime history of schizophrenia or other psychotic disorder, bipolar disorder, obsessive-compulsive disorder (ocd), eating or feeding disorder, neurodevelopmental disorder, or neurocognitive disorder; * any neuropsychiatric disorder that is judged to be the primary presenting problem, other than that which is specified as study group eligibility criteria; * substance use disorder within the past 1 year; * urine toxicology positive for illicit drugs or dis-allowed concomitant medications as per study protocol; intermittent cannabis use that does not meet criteria for a substance use disorder may be permitted under the protocol. * suicidal ideation or risk of self-harm that is judged by the pi to be clinically significant and to warrant intervention * concurrent treatment with opioid medication, or with long-acting or daytime short-acting benzodiazepines within two weeks of study start * current cognitive impairment, as defined by a score \<23 on the montreal cognitive assessment (moca) * estimated iq \<80 * currently receiving evidence-based psychotherapy for ptsd (e.g., prolonged exposure, cognitive processing therapy).
a prospective, observational study of copd patients in u.s. hospitals

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this is an observational study to evaluate the relationship between pulmonary function and the patient reported health-related quality of life (hrqol) and chronic obstructive pulmonary disease (copd) related admissions. patients with copd will be approached to participate in the study. pulmonary function will be measured on consented, eligible patients. the pulmonary function measurement collected will be used for cohort assignment. the prospective follow up period will monitor the cohorts for evidence of readmission and to assess hrqol.


Eligibility criteria:
inclusion criteria: ≥ 18 years of age fluent in english current hospital admission is for copd diagnosis of copd for at least 1 year prior to enrollment exclusion criteria: unwilling or unable to provide informed consent
analysis of prevalence and risk factors associated with gastroesophageal reflux disease and esophagitis after peroral endoscopic myotomy

Conditions: Achalasia; GERD

Summary: achalasia is an uncommon disorder that results from the degeneration of ganglion cells of the myenteric plexus in the lower esophageal wall. peroral endoscopic myotomy (poem) is a minimally invasive procedure capable of overcoming limitations of achalasia treatments. this study aimed to: 1) identify the prevalence of reflux esophagitis and asymptomatic gerd in patients who underwent poem, and 2) evaluate patient and intraprocedural variables associated with post-poem gerd.


Eligibility criteria:
inclusion criteria: 1. males and females who are 18 years of age and older and are willing to sign an informed consent form (icf) 2. achalasia patients who underwent poem exclusion criteria: 1. lack of written consent for participation in the study 2. conditions which are contraindication to esophagogastroscopy and high-resolution esophageal manometry

Keywords: peroral endoscopic myotomy high-resolution esophageal manometry
frequency of formula change prior to the accurate diagnosis of pyloric stenosis

Conditions: Pyloric Stenosis

Summary: the purpose of this study is to determine if there is an increase in the frequency of formula change in patients with pyloric sctenosis prior to being correctly diagnosed.

the study can be described as a prospective and retrospective study in which information will be gathered from questionnaires, analysis of medical records, and the information obtained from diagnostic procedures (i.e. laboratory results, ultrasonography). the time of enrollment will be at the time of hospital admission for the study group and the control group. the length of time for which the patient will be involved with the study will coincide with the length of stay in the hospital. this will be a single center trial involving maimonides medical center. approximately 50-100 subjects will be enrolled overall to give the study more credibility. methods and procedures: 1. study participants: all patients admitted to maimonides medical center with a diagnosis of pyloric stenosis two to nine weeks of age. patients will be excluded from the study if there is a diagnosed milk allergy, history of prior abdominal surgery, or history of prematurity or metabolic disease. controls will be made up of the same age range, with similar exclusion criteria, and will consist of patients admitted for other reasons than listed above, such as bronchiolitis and rule out sepsis. 2: data: data will be received through the completion of questionnaire. 3. data collection and processing: questionnaire responses will be analyzed and the responses will be statistically analyzed for correlation. benefits: through participation in this study, patients may help future patients diagnosed with pyloric stenosis be brought to the attention of a medical professional. risks: with maintenance of confidentiality, risks to participants in this study are negligible.

Eligibility criteria:
inclusion criteria: * infants ages 2-9 weeks exclusion criteria: * infant not ages 2-9 weeks or patients with history of medical problems

Keywords: pyloric stenosis
effect of ethanol and genetic polymorphisms on bupropion metabolism

Conditions: Alcohol Drinking; Depression; Smoking Cessation; Attention Deficit Disorder

Summary: the two purposes of this study are 1. to determine what effect the chronic and moderate/heavy drinking of alcoholic beverages has 1. on the blood level of bupropion and chlorzoxazone and their major breakdown products in the blood and 2. on the stimulant effect of bupropion and 2. to determine what effect a normal and common (25% frequency) genetic variation of a specific liver enzyme (that breaks down bupropion) has 1. on the blood levels of bupropion and its major breakdown products in the blood and 2. on the stimulant effect of bupropion. two groups of volunteers will be recruited for this study: 1. volunteers who drink moderate to heavy amounts of alcohol frequently and 2. volunteers who usually do not drink alcohol. volunteers will not be asked to change their drinking (or nondrinking) habits during the study.


Eligibility criteria:
inclusion criteria: * healthy adults who are 21 - 55 years of age. * either 1) moderate-to-heavy drinkers who drink on average more than 14 but less than 28 drinks per week; or 2) adults who normally abstain from drinking alcohol. exclusion criteria: * participants who are currently taking prescription medications (including oral contraceptives) * pregnancy * body mass index (bmi) greater than 30 * history of seizures or eating disorders

Keywords: alcohol bupropion chlorzoxazone interaction induction depression smoking drinking cytochrome p450 enzyme cyp2b6 cyp2e1 pharmacogenetics pharmacokinetics pharmacodynamics boston tufts university